Literature DB >> 21531633

Risk factors for antiepileptic drug regimen change in patients with newly diagnosed epilepsy.

Marianne C Cunnington1, David J Webb, Michael C Irizarry, Ranjani Manjunath.   

Abstract

This study aimed to investigate the evolution of treatment within patients with newly diagnosed epilepsy identified from a large US commercial health care database. Postdiagnosis, patient follow-up was divided into observation units defined by consecutive antiepileptic drug (AED) prescriptions. Consecutive prescriptions were compared to assess whether a change in AED regimen had occurred. Factors associated with a regimen change were explored using a logistic regression model with subject random effects. Among 5930 patients with newly diagnosed epilepsy, there was a median of one regimen change in the first year. However, patients prescribed polytherapy regimens early in the course of disease were at a substantially greater risk of a regimen change (polytherapy vs monotherapy odds ratio=10.2, 95% confidence interval=9.2-11.3). Although a seizure during the preceding 90 days significantly increased the risk of a regimen change, it was beyond the scope of the study to determine the proportion of changes directly attributable to uncontrolled seizures.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531633     DOI: 10.1016/j.yebeh.2011.03.017

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  2 in total

1.  Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan.

Authors:  Abla Albsoul-Younes; Lubna Gharaibeh; Amer A Murtaja; Amira Masri; Ibrahim Alabbadi; Abdelkarim A Al-Qudah
Journal:  Neurosciences (Riyadh)       Date:  2016-07       Impact factor: 0.906

2.  Treatment of epilepsy in China: Formal or informal.

Authors:  Jianming Liu; Zhiliang Liu; Tao Chen; Ruxiang Xu
Journal:  Neural Regen Res       Date:  2013-12-15       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.